🇺🇸 FDA
Pipeline program

Belzutifan, CABOZANTINIB , Lenvatinib, Lenvatinib

MK-6482-011

Phase 3 small_molecule active

Quick answer

Belzutifan, CABOZANTINIB , Lenvatinib, Lenvatinib for Advanced RCC with clear cell component is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Advanced RCC with clear cell component
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials